Harbor Capital Advisors Inc. Has $983,000 Stock Holdings in Natera, Inc. $NTRA

Key Points

• Harbor Capital Advisors Inc. reduced its stake in Natera, Inc. by 42.5%, owning 5,821 shares worth approximately $983,000 after selling 4,310 shares in the second quarter.
• Natera reported a quarterly loss with earnings per share of ($0.74), falling short of the expected ($0.60), despite a 32.2% increase in revenue year-over-year to $546.60 million.
• Analysts remain positive on Natera, with multiple firms retaining an "overweight" rating and price targets ranging from $183.00 to $220.00.

Harbor Capital Advisors Inc. reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 42.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,821 shares of the medical research company's stock after selling 4,310 shares during the quarter. Harbor Capital Advisors Inc.'s holdings in Natera were worth $983,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of Jackson Hole Trust purchased a new stake in shares of Natera during the first quarter worth approximately $29,000. Rakuten Securities Inc. increased its holdings in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares during the last quarter. TCTC Holdings LLC increased its holdings in shares of Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after acquiring an additional 124 shares during the last quarter. ORG Partners LLC acquired a new stake in shares of Natera in the 1st quarter valued at about $32,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after purchasing an additional 106 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Up 0.7%

NTRA traded up $1.25 during midday trading on Friday, reaching $181.11. 1,489,046 shares of the company's stock were exchanged, compared to its average volume of 858,746. The firm has a market capitalization of $24.86 billion, a price-to-earnings ratio of -94.82 and a beta of 1.68. Natera, Inc. has a one year low of $117.27 and a one year high of $183.00. The business has a 50-day simple moving average of $156.80 and a two-hundred day simple moving average of $155.09.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business's quarterly revenue was up 32.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Stephens reissued an "overweight" rating and set a $183.00 price target on shares of Natera in a research report on Friday, August 15th. Cowen restated a "buy" rating on shares of Natera in a report on Friday, August 8th. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a report on Monday, July 28th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $220.00 target price (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $194.00.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer directly owned 65,430 shares of the company's stock, valued at $8,990,082. This trade represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rowan E. Chapman sold 2,750 shares of the business's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the sale, the director directly owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,423 shares of company stock valued at $8,459,656. 5.63% of the stock is owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.